Irsogladine maleate

Key Product Details

Product Description

Irsogladine maleate is a phosphodiesterase 4 (PDE4) inhibitor that displays gastroprotective properties. Prevents gastric mucosal injury induced by monochloramine and ischemia-reperfusion. Activates gap-junctional intercellular communication improving gastric mucosal barrier function. Inhibits superoxide production in human neutrophils and inhibits in vitro and in vivo angiogenesis.

Product Specifications for Irsogladine maleate

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for Irsogladine maleate

The following data is based on the product molecular weight 372.18.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.69 mL	13.43 mL	26.87 mL
5 mM	0.54 mL	2.69 mL	5.37 mL
10 mM	0.27 mL	1.34 mL	2.69 mL
50 mM	0.05 mL	0.27 mL	0.54 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Kyoi Phosphodiesterase type IV inhibitors prevent ischemia-reperfusion-induced gastric injury in rats. J.Pharmacol.Sci. 2004 PMID: 15272207
• Kyoi Irsogladine, an anti-ulcer drug, suppresses superoxide production by inhibiting phosphodiesterase type 4 in human neutrophils. Life Sci. 2004 PMID: 15501481
• Nozaki Inhibition of breast cancer regrowth and pulmonary metastasis in nude mice by anti-gastric ulcer agent, irsogladine. Breast Cancer Res.Treat. 2004 PMID: 14758089

Product Documents for Irsogladine maleate